Association Between Circulating Ketone Bodies and Worse Outcomes in Hemodialysis Patients

Masaru Obokata1, Kazuaki Negishi2,3, Hiroaki Sunaga1

  • 1Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

Insights

Elevated serum β-hydroxybutyrate (βOHB) levels in hemodialysis patients correlate with a higher risk of cardiovascular events and death. This finding suggests βOHB may be a significant biomarker for adverse outcomes in this population.

Area of Science:

  • Nephrology
  • Cardiology
  • Metabolic Science

Background:

  • Cardiovascular disease (CVD) is a primary cause of death in hemodialysis patients.
  • Metabolic disturbances are common in patients with high cardiovascular risk.
  • The role of ketone bodies in hemodialysis patient outcomes requires further investigation.

Purpose of the Study:

  • To investigate the association between serum β-hydroxybutyrate (βOHB) levels and clinical outcomes in hemodialysis patients.
  • To determine if βOHB can serve as a predictive biomarker for cardiovascular events and mortality.

Main Methods:

  • Retrospective analysis of 405 stable hemodialysis patients.
  • Measurement of serum βOHB levels.
  • Follow-up for major adverse cardiovascular events (MACE) and all-cause mortality.

Main Results:

  • Higher serum βOHB levels were linked to increased rates of MACE and all-cause death.
  • The highest βOHB quintile showed a significantly elevated risk of MACE (HR, 10.2; P<0.001) after adjustment.
  • βOHB levels independently and incrementally predicted MACE, outperforming established risk scores.

Conclusions:

  • Increased serum βOHB is an independent predictor of cardiovascular events and mortality in hemodialysis patients.
  • These findings underscore the potential clinical utility of βOHB as a prognostic marker.
  • Further research is needed to elucidate the underlying mechanisms connecting βOHB to adverse outcomes.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
758
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.1K
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.6K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
820